Base de dados : MEDLINE
Pesquisa : D06.472.699.327.740.320.340 [Categoria DeCS]
Referências encontradas : 1558 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 156 ir para página                         

  1 / 1558 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463149
[Au] Autor:Lawton CAF; Lin X; Hanks GE; Lepor H; Grignon DJ; Brereton HD; Bedi M; Rosenthal SA; Zeitzer KL; Venkatesan VM; Horwitz EM; Pisansky TM; Kim H; Parliament MB; Rabinovitch R; Roach M; Kwok Y; Dignam JJ; Sandler HM
[Ad] Endereço:Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: clawton@mcw.edu.
[Ti] Título:Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):296-303, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Trial RTOG 9202 was a phase 3 randomized trial designed to determine the optimal duration of androgen deprivation therapy (ADT) when combined with definitive radiation therapy (RT) in the treatment of locally advanced nonmetastatic adenocarcinoma of the prostate. Long-term follow-up results of this study now available are relevant to the management of this disease. METHODS AND MATERIALS: Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) <150 ng/mL and no evidence of distant metastasis were randomized (June 1992 to April 1995) to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month) and definitive RT versus long-term ADT (LTAD: STAD with definitive RT plus an additional 24 months of monthly goserelin). RESULTS: Among 1520 protocol-eligible and evaluable patients, the median follow-up time for this analysis was 19.6 years. In analysis adjusted for prognostic covariates, LTAD improved disease-free survival (29% relative reduction in failure rate, P<.0001), local progression (46% relative reduction, P=.02), distant metastases (36% relative reduction, P<.0001), disease-specific survival (30% relative reduction, P=.003), and overall survival (12% relative reduction, P=.03). Other-cause mortality (non-prostate cancer) did not differ (5% relative reduction, P=.48). CONCLUSIONS: LTAD and RT is superior to STAD and RT for the treatment of locally advanced nonmetastatic adenocarcinoma of the prostate and should be considered the standard of care.
[Mh] Termos MeSH primário: Adenocarcinoma/terapia
Antagonistas de Androgênios/uso terapêutico
Neoplasias da Próstata/terapia
[Mh] Termos MeSH secundário: Adenocarcinoma/sangue
Adenocarcinoma/mortalidade
Adenocarcinoma/patologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Antagonistas de Androgênios/administração & dosagem
Antagonistas de Androgênios/efeitos adversos
Terapia Combinada/efeitos adversos
Terapia Combinada/métodos
Terapia Combinada/estatística & dados numéricos
Intervalo Livre de Doença
Flutamida/administração & dosagem
Flutamida/efeitos adversos
Flutamida/uso terapêutico
Seguimentos
Gosserrelina/administração & dosagem
Gosserrelina/efeitos adversos
Gosserrelina/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/sangue
Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/patologia
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Androgen Antagonists); 0F65R8P09N (Goserelin); 76W6J0943E (Flutamide); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  2 / 1558 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187457
[Au] Autor:Chen MY; Chen YY; Tsai HT; Tzai TS; Chen MC; Tsai YS
[Ad] Endereço:Department of Urology, Madou Sin-Lau Hospital, Sin-Lau Medical Foundation, the Presbyterian Church in Taiwan, Tainan, Taiwan, R.O.C.
[Ti] Título:Transdermal Delivery of Luteinizing Hormone-releasing Hormone with Chitosan Microneedles: A Promising Tool for Androgen Deprivation Therapy.
[So] Source:Anticancer Res;37(12):6791-6797, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Long-term administration of luteinizing hormone-releasing hormone analogs (LHRHa) is the main type of androgen-deprivation therapy (ADT) for lethal prostate cancer. A fully insertable microneedle system, composed of embeddable chitosan microneedles and a dissolvable polyvinyl alcohol/polyvinyl pyrrolidone supporting array, was developed for sustained delivery of LHRHa to the skin. A porcine cadaver skin test showed that chitosan microneedles can be fully embedded within the skin and microneedle-created micropores reseal within 7 days. The measured LHRHa loading amount was 73.3±2.8 µg per microneedle patch. After applying goserelin-containing microneedles to mice, serum LH levels increased initially and then declined below baseline at day 7. In contrast, serum testosterone levels increased to reach a peak at day 14 and then declined to a castration level at day 21. Additionally, such a castration level was maintained for 2 weeks. Therefore, transdermal delivery of goserelin with embeddable chitosan microneedles can produce a castrated state in mice. Such a system is a promising, feasible means of delivering ADT.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/administração & dosagem
Quitosana/química
Sistemas de Liberação de Medicamentos/métodos
Hormônio Liberador de Gonadotropina/administração & dosagem
Agulhas
[Mh] Termos MeSH secundário: Administração Cutânea
Antagonistas de Androgênios/química
Antagonistas de Androgênios/farmacocinética
Animais
Antineoplásicos Hormonais/administração & dosagem
Antineoplásicos Hormonais/química
Antineoplásicos Hormonais/farmacocinética
Hormônio Liberador de Gonadotropina/química
Hormônio Liberador de Gonadotropina/farmacocinética
Gosserrelina/administração & dosagem
Gosserrelina/química
Gosserrelina/farmacocinética
Seres Humanos
Hormônio Luteinizante/sangue
Masculino
Camundongos Endogâmicos ICR
Pele/metabolismo
Suínos
Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Antineoplastic Agents, Hormonal); 0F65R8P09N (Goserelin); 33515-09-2 (Gonadotropin-Releasing Hormone); 3XMK78S47O (Testosterone); 9002-67-9 (Luteinizing Hormone); 9012-76-4 (Chitosan)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  3 / 1558 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29017178
[Au] Autor:Haque R; UlcickasYood M; Xu X; Cassidy-Bushrow AE; Tsai HT; Keating NL; Van Den Eeden SK; Potosky AL
[Ad] Endereço:Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101, USA.
[Ti] Título:Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
[So] Source:Br J Cancer;117(8):1233-1240, 2017 Oct 10.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: As androgen deprivation therapy (ADT) is increasingly being used in men with localised prostate cancer, our goal was to examine the association between ADT and the risk of cardiovascular disease (CVD). METHODS: We conducted a prospective cohort study using records of a large health-care system in California. The study included men with newly diagnosed localised prostate cancer (1998-2008) who initially underwent active surveillance (N=7637) and were followed through 2010. We examined 10 individual CVD outcomes. Cox proportional hazard models incorporated time-varying treatment variables and controlled for race/ethnicity, age, and tumour characteristics, recurrence risk, CVD medication use, and CVD risk factors. RESULTS: Of the 7637 subjects, nearly 30% were exposed to ADT. In the multivariable analyses, ADT was associated with an increased risk of heart failure (adjusted HR=1.81, 95% CI 1.40-2.32) in men without preexisting CVD. Elevated risks of arrhythmia (adjusted HR=1.44, 95% CI 1.02-2.01), and conduction disorder (adjusted HR=3.11, 95% CI 1.22, 7.91) were only observed among patients with preexisting CVD. CONCLUSIONS: In men with clinically localised prostate cancer who were initially under active surveillance, ADT was associated with a greater risk of heart failure in men without any preexisting CVD. We also found an increased risk of arrhythmia and conduction disorder in men with preexisting CVD. This study provides the basis for identifying high-risk men treated with ADT who might benefit from regular cardiac monitoring and lifestyle modification recommendations.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/uso terapêutico
Antineoplásicos Hormonais/uso terapêutico
Arritmias Cardíacas/epidemiologia
Insuficiência Cardíaca/epidemiologia
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Anilidas/uso terapêutico
California/epidemiologia
Doenças Cardiovasculares/epidemiologia
Estudos de Coortes
Flutamida/uso terapêutico
Hormônio Liberador de Gonadotropina/agonistas
Gosserrelina/uso terapêutico
Seres Humanos
Imidazolidinas/uso terapêutico
Leuprolida/uso terapêutico
Masculino
Meia-Idade
Análise Multivariada
Gradação de Tumores
Nitrilos/uso terapêutico
Modelos de Riscos Proporcionais
Estudos Prospectivos
Neoplasias da Próstata/epidemiologia
Neoplasias da Próstata/patologia
Fatores de Risco
Compostos de Tosil/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Anilides); 0 (Antineoplastic Agents, Hormonal); 0 (Imidazolidines); 0 (Nitriles); 0 (Tosyl Compounds); 0F65R8P09N (Goserelin); 33515-09-2 (Gonadotropin-Releasing Hormone); 51G6I8B902 (nilutamide); 76W6J0943E (Flutamide); A0Z3NAU9DP (bicalutamide); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171011
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2017.280


  4 / 1558 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28885430
[Au] Autor:Song M; Glasgow M; Murugan P; Rivard C
[Ad] Endereço:Department of Obstetrics, Gynecology and Women's Health and the Department of Pathology and Laboratory Medicine, University of Minnesota, Minneapolis, Minnesota.
[Ti] Título:Aggressive Angiomyxoma of the Vulva and Bladder.
[So] Source:Obstet Gynecol;130(4):885-888, 2017 Oct.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Aggressive angiomyxoma is a rare, locally infiltrative tumor, frequently occurring in female patients. Although wide local excision is considered standard therapy, radical surgery may be needed. CASE: A 49-year-old woman presented with an aggressive angiomyxoma involving the vulva and bladder. Given the hormone receptor status and size of the tumor, the patient was initially treated with fulvestrant and goserelin acetate in an attempt to reduce the size of the mass. She was followed up at 1- to 3-month intervals; after 6 months of treatment, owing to increasing size of the mass and worsening symptoms, the decision was made to proceed with radical surgery. CONCLUSION: Although a less radical surgical approach is preferred, radical surgery is possible for treatment of aggressive angiomyxoma when needed.
[Mh] Termos MeSH primário: Mixoma/diagnóstico
Neoplasias da Bexiga Urinária/diagnóstico
Neoplasias Vulvares/diagnóstico
[Mh] Termos MeSH secundário: Antineoplásicos Hormonais/administração & dosagem
Diagnóstico Diferencial
Estradiol/administração & dosagem
Estradiol/análogos & derivados
Feminino
Gosserrelina/administração & dosagem
Seres Humanos
Meia-Idade
Mixoma/tratamento farmacológico
Mixoma/cirurgia
Terapia Neoadjuvante
Invasividade Neoplásica
Neoplasias da Bexiga Urinária/tratamento farmacológico
Neoplasias da Bexiga Urinária/cirurgia
Neoplasias Vulvares/tratamento farmacológico
Neoplasias Vulvares/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0F65R8P09N (Goserelin); 22X328QOC4 (fulvestrant); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170909
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002254


  5 / 1558 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28394498
[Au] Autor:Mason M; Richaud P; Bosnyak Z; Malmberg A; Neijber A
[Ad] Endereço:School of Medicine, Institute of Cancer and Genetics, Cardiff University, Cardiff, UK.
[Ti] Título:Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
[So] Source:Low Urin Tract Symptoms;9(2):82-88, 2017 May.
[Is] ISSN:1757-5672
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: In patients with prostate cancer (PCa), prostate enlargement may give rise to lower urinary tract symptoms (LUTS); many patients suffer from moderate-to-severe symptoms. We compare the efficacy of degarelix and goserelin plus bicalutamide in improving LUTS in PCa patients. METHODS: Data were pooled from three Phase 3, randomized clinical trials of once-monthly treatment for 12 weeks with degarelix (240/80 mg; n = 289) or goserelin (3.6 mg) plus bicalutamide (50 mg; n = 174) for initial flare protection. LUTS at weeks 4, 8, and 12 were compared to baseline. Clinically relevant LUTS relief was a ≥3-point International Prostate Symptom Score (IPSS) decrease. Adverse events were assessed throughout the trials. RESULTS: Patients receiving degarelix had significantly greater decreases in IPSS vs. goserelin at week 12 (adjusted difference: -1.24; 95% CI -2.33 to -0.14, P = 0.03). Clinically relevant LUTS relief with degarelix was especially pronounced in patients with moderate-to-severe LUTS (baseline IPSS ≥13) (odds ratio; OR 2.31; 95% CI 1.19-4.47, P = 0.01) and advanced PCa (OR 2.36; 95% CI 1.10-5.04, P = 0.03). A twofold higher OR for early (week 4) LUTS relief was seen with degarelix vs. goserelin (OR 2.03; 95% CI 1.14-3.60, P = 0.02). No difference in total prostate volume or urinary tract infection-related adverse events (2%) was seen between treatment groups. CONCLUSION: An early, significant and clinically more pronounced improvement of LUTS, especially in patients with moderate-to-severe LUTS or advanced PCa, was seen with degarelix vs. goserelin plus bicalutamide.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/administração & dosagem
Anilidas/administração & dosagem
Antineoplásicos Hormonais/administração & dosagem
Gosserrelina/administração & dosagem
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Nitrilos/administração & dosagem
Oligopeptídeos/administração & dosagem
Compostos de Tosil/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Análise de Variância
Esquema de Medicação
Seres Humanos
Sintomas do Trato Urinário Inferior/etiologia
Sintomas do Trato Urinário Inferior/patologia
Masculino
Tamanho do Órgão
Próstata/patologia
Antígeno Prostático Específico/metabolismo
Neoplasias da Próstata/complicações
Neoplasias da Próstata/tratamento farmacológico
Neoplasias da Próstata/patologia
Testosterona/metabolismo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Anilides); 0 (Antineoplastic Agents, Hormonal); 0 (Nitriles); 0 (Oligopeptides); 0 (Tosyl Compounds); 0 (acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide); 0F65R8P09N (Goserelin); 3XMK78S47O (Testosterone); A0Z3NAU9DP (bicalutamide); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170411
[St] Status:MEDLINE
[do] DOI:10.1111/luts.12114


  6 / 1558 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28024943
[Au] Autor:Zhang P; Li CZ; Jiao GM; Zhang JJ; Zhao HP; Yan F; Jia SF; Hu BS; Wu CT
[Ad] Endereço:College of Nursing and Rehabilitation, North China University of Science and Technology, Tangshan 063009, Hebei, China.
[Ti] Título:Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials.
[So] Source:Eur J Surg Oncol;43(7):1161-1172, 2017 Jul.
[Is] ISSN:1532-2157
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The effect of ovarian ablation or suppression (OAS) in premenopausal women with breast cancer is controversial. The overall survival (OS), disease-free survival (DFS) and adverse event of OAS versus no OAS were compared. METHODS: A literature review of EMBASE, Web of Science, PUBMED, and Cochrane Library was conducted. The hazard ratio (HR) and 95% confidence interval (CI) for OS and DFS, as well as risk ratio (RR) and 95% CI for adverse events were evaluated. I-squared statistic (I ) represents heterogeneity. RESULTS: Twenty-nine studies with a total of 21,249 women were included. In premenopausal women aged 40 years or younger, there were significant differences in OS (HR 0.78, 95% CI: 0.66-0.94, P=0.008, I = 0%) and DFS (HR 0.84, 95% CI: 0.73-0.97, P=0.02, I = 0%) between OAS and no OAS. In advanced stage breast cancer, a significant difference was found in OS (HR 0.76, 95% CI: 0.60-0.96, P=0.02, I = 0%). Patients treated with OAS had more chances to have hot flushes (RR 1.91, 95% CI: 1.62-2.26, P < 0.01, I = 0%) and vaginal dryness (RR 1.19, 95% CI: 1.08-1.31, P=0.0003, I = 0%). No significant difference in depression (RR 1.28, 95% CI: 0.94-1.74, P=0.12, I = 0%). CONCLUSIONS: The study shows that OAS plays a beneficial role in premenopausal women aged 40 years or younger and advanced stage breast cancer. However, OAS is associated with increase in hot flushes and vaginal dryness.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias da Mama/terapia
Hormônio Liberador de Gonadotropina/agonistas
Ovariectomia
[Mh] Termos MeSH secundário: Neoplasias da Mama/patologia
Terapia Combinada
Intervalo Livre de Doença
Feminino
Gosserrelina/administração & dosagem
Gosserrelina/efeitos adversos
Seres Humanos
Leuprolida/administração & dosagem
Leuprolida/efeitos adversos
Metástase Linfática
Estadiamento de Neoplasias
Ovariectomia/efeitos adversos
Pré-Menopausa
Ensaios Clínicos Controlados Aleatórios como Assunto
Taxa de Sobrevida
Tamoxifeno/administração & dosagem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
094ZI81Y45 (Tamoxifen); 0F65R8P09N (Goserelin); 33515-09-2 (Gonadotropin-Releasing Hormone); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170818
[Lr] Data última revisão:
170818
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161228
[St] Status:MEDLINE


  7 / 1558 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27756786
[Au] Autor:Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
[Ad] Endereço:Princess Margaret Cancer Centre, Toronto, Canada.
[Ti] Título:A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
[So] Source:Clin Cancer Res;23(8):1974-1980, 2017 04 15.
[Is] ISSN:1078-0432
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Degarelix, a new gonadotropin-releasing hormone (GnRH) receptor antagonist with demonstrated efficacy as first-line treatment in the management of high-risk prostate cancer, possesses some theoretical advantages over luteinizing hormone-releasing hormone (LHRH) analogues in terms of avoiding "testosterone flare" and lower follicle-stimulating hormone (FSH) levels. We set out to determine whether preoperative degarelix influenced surrogates of disease control in a randomized phase II study. Thirty-nine patients were randomly assigned to one of three different neoadjuvant arms: degarelix only, degarelix/bicalutamide, or LHRH agonist/bicalutamide. Treatments were given for 3 months before prostatectomy. Patients had localized prostate cancer and had chosen radical prostatectomy as primary treatment. The primary end point was treatment effect on intratumoral dihydrotestosterone levels. Intratumoral DHT levels were higher in the degarelix arm than both the degarelix/bicalutamide and LHRH agonist/bicalutamide arms (0.87 ng/g vs. 0.26 ng/g and 0.23 ng/g, < 0.01). No significant differences existed for other intratumoral androgens, such as testosterone and dehydroepiandrosterone. Patients in the degarelix-only arm had higher AMACR levels on immunohistochemical analysis ( = 0.01). Serum FSH levels were lower after 12 weeks of therapy in both degarelix arms than the LHRH agonist/bicalutamide arm (0.55 and 0.65 vs. 3.65, < 0.01), and inhibin B levels were lower in the degarelix/bicalutamide arm than the LHRH agonist/bicalutamide arm (82.14 vs. 126.67, = 0.02). Neoadjuvant degarelix alone, compared with use of LHRH agonist and bicalutamide, is associated with higher levels of intratumoral dihydrotestosterone, despite similar testosterone levels. Further studies that evaluate the mechanisms behind these results are needed. .
[Mh] Termos MeSH primário: Adenocarcinoma/tratamento farmacológico
Antineoplásicos Hormonais/administração & dosagem
Oligopeptídeos/administração & dosagem
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antagonistas de Androgênios/administração & dosagem
Anilidas/administração & dosagem
Quimioterapia Adjuvante/métodos
Hormônio Liberador de Gonadotropina/agonistas
Gosserrelina/administração & dosagem
Seres Humanos
Imuno-Histoquímica
Leuprolida/administração & dosagem
Masculino
Meia-Idade
Terapia Neoadjuvante/métodos
Nitrilos/administração & dosagem
Oligopeptídeos/efeitos adversos
Prostatectomia
Receptores LHRH/antagonistas & inibidores
Análise Serial de Tecidos
Compostos de Tosil/administração & dosagem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Anilides); 0 (Antineoplastic Agents, Hormonal); 0 (Nitriles); 0 (Oligopeptides); 0 (Receptors, LHRH); 0 (Tosyl Compounds); 0 (acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide); 0F65R8P09N (Goserelin); 33515-09-2 (Gonadotropin-Releasing Hormone); A0Z3NAU9DP (bicalutamide); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1158/1078-0432.CCR-16-1790


  8 / 1558 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27684440
[Au] Autor:Zhu W; Xu H; Ma J; Guo J; Xue W; Gu B; Sheng L; Yao X; Sun F; Gong J; Qiu W; Ding Q; Jiang H
[Ad] Endereço:Department and Institute of Urology, Huashan Hospital, Shanghai, China.
[Ti] Título:An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
[So] Source:Urol Int;98(1):79-84, 2017.
[Is] ISSN:1423-0399
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The study aimed to evaluate the effects of metformin on insulin, C-peptide and body weight in Chinese men undergoing androgen deprivation therapy (ADT). METHODS: Between March 2013 and June 2014, 62 newly diagnosed patients of prostate cancer (PCa) due to receive ADT were recruited from 7 hospitals in Shanghai. Patients were randomized to respectively receive ADT (n = 31) and ADT + metformin (n = 31) for 6 months. Fasting and postprandial serum levels of insulin and C-peptide, blood glucose, prostate specific antigen, body mass index (BMI) and waist circumference (WC) were measured at the beginning and end of 6-month treatment. RESULTS: Baseline characteristics were comparable between the 2 groups. Controlling for baseline levels, the ADT group had significantly higher levels of fasting glucose (p = 0.01) and higher WC (p = 0.04) than the ADT + metformin group. The levels of insulin, C-peptide and BMI did not differ significantly. CONCLUSIONS: Metformin may be potentially efficient as a concomitant therapy on patients with PCa undergoing androgen deprivation treatment.
[Mh] Termos MeSH primário: Hipoglicemiantes/uso terapêutico
Metformina/uso terapêutico
Neoplasias da Próstata/terapia
[Mh] Termos MeSH secundário: Idoso
Antagonistas de Androgênios/uso terapêutico
Anilidas/uso terapêutico
Antineoplásicos Hormonais/uso terapêutico
Terapia Combinada
Gosserrelina/uso terapêutico
Seres Humanos
Masculino
Nitrilos/uso terapêutico
Orquiectomia
Projetos Piloto
Compostos de Tosil/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Anilides); 0 (Antineoplastic Agents, Hormonal); 0 (Hypoglycemic Agents); 0 (Nitriles); 0 (Tosyl Compounds); 0F65R8P09N (Goserelin); 9100L32L2N (Metformin); A0Z3NAU9DP (bicalutamide)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170413
[Lr] Data última revisão:
170413
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160930
[St] Status:MEDLINE
[do] DOI:10.1159/000448691


  9 / 1558 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27847099
[Au] Autor:Shen YC; Kang CH; Chiang PH
[Ad] Endereço:Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Cheng Shiu University, Kaohsiung, Taiwan.
[Ti] Título:Efficacy of switching therapy of luteinizing hormone-releasing hormone analogue for advanced prostate cancer.
[So] Source:Kaohsiung J Med Sci;32(11):567-571, 2016 Nov.
[Is] ISSN:1607-551X
[Cp] País de publicação:China (Republic : 1949- )
[La] Idioma:eng
[Ab] Resumo:This study was conducted to determine the efficacy of switching therapy with a second-line luteinizing hormone-releasing hormone (LHRH) analogue after prostate-specific antigen (PSA) progression for advanced prostate cancer. We enrolled 200 patients, from December 2005 to September 2013, with nodal positive, metastatic prostate cancer or disease progression after definite treatment receiving continuous LHRH analogue therapy with monthly depot leuprorelin(sc) acetate 3.75 mg/vial (LA) or goserelin acetate(sc) 3.6 mg/vial (GA). If the patients had castration-resistant prostate cancer, the treatment choice of switching therapy (from LA to GA or from GA to LA) prior to starting chemotherapy was given. The LH, testosterone level, and PSA change were recorded. The records showed that there were 127 patients receiving LA as initial ADT therapy, whereas the other 73 patients were in GA therapy. A total of 92 patients received LHRH analogue switching therapy (54 patients switched from LA to GA and 38 switched from GA to LA). The effect of LH and testosterone reduction prior to and after switching therapy was comparable between the two groups, and increased PSA level after 3 months of treatment was seen in both groups (median PSA: 15.7-67.7 ng/mL in the LA to GA group; 15.2-71.4 ng/mL in the GA to LA group). This study concluded that switching therapy for patients with PSA progression after ADT has no efficacy of further PSA response.
[Mh] Termos MeSH primário: Hormônio Liberador de Gonadotropina/metabolismo
Hormônio Liberador de Gonadotropina/uso terapêutico
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Gosserrelina/uso terapêutico
Seres Humanos
Leuprolida/uso terapêutico
Masculino
Antígeno Prostático Específico/metabolismo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0F65R8P09N (Goserelin); 33515-09-2 (Gonadotropin-Releasing Hormone); EC 3.4.21.77 (Prostate-Specific Antigen); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161117
[St] Status:MEDLINE


  10 / 1558 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27723388
[Au] Autor:Davis BM; Goldstraw E; Bhowmik A; José RJ
[Ad] Endereço:Core Medicine Trainee in the Department of Respiratory Medicine, Homerton University Hospital, London.
[Ti] Título:A gynaecological cause of spontaneous haemopneumothorax.
[So] Source:Br J Hosp Med (Lond);77(10):602-603, 2016 Oct.
[Is] ISSN:1750-8460
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Endometriose/complicações
Hemopneumotórax/etiologia
Doenças Torácicas/complicações
[Mh] Termos MeSH secundário: Antineoplásicos Hormonais/uso terapêutico
Endometriose/diagnóstico por imagem
Endometriose/tratamento farmacológico
Feminino
Gosserrelina/uso terapêutico
Hemopneumotórax/diagnóstico por imagem
Seres Humanos
Imagem por Ressonância Magnética
Meia-Idade
Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único
Doenças Torácicas/diagnóstico por imagem
Doenças Torácicas/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0F65R8P09N (Goserelin)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170309
[Lr] Data última revisão:
170309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161011
[St] Status:MEDLINE



página 1 de 156 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde